COLL News and Press, Collegium Pharmaceutical Inc. From 06/01/23

STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a f...

2023-05-25 08:14:35 ET Summary I am turning more constructive on Collegium following the outlook on its Q1 numbers. It came in with record product revenues, the perfect complement to the excellent returns on capital invested. The market expectations for COLL going forward are ...

2023-05-06 22:16:07 ET Collegium Pharmaceutical, Inc. (COLL) Q1 2023 Earnings Conference Call May 4, 2023 16:30 ET Company Participants Christopher James - Vice President, Investor Relations Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial ...

2023-05-04 17:00:28 ET Collegium Pharmaceutical press release ( NASDAQ: COLL ): Q1 Non-GAAP EPS of $1.32 misses by $0.19 . Revenue of $144.8M (+72.9% Y/Y) beats by $6.47M . FY23 Product Revenues, Net expected in the range of $565.0 to $580.0 million, Adjusted O...

– Generated Record Net Revenue of $144.8 Million – – Delivered Record Belbuca ® and Xtampza ® ER Net Revenue – – Ended Q1’23 with Cash Balance of $269.5 Million – – Reaffirmed Full Year 202...

STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2023...

2023-04-13 16:47:55 ET The U.S. Food and Drug Administration (FDA) issued new labeling requirements for opioid pain medications on Thursday, adding warnings about potential drug-induced reactions such as a rise in pain or pain sensitivity. Labeling changes include restrictions on the ...

STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a ...

The following slide deck was published by Collegium Pharmaceutical, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Collegium Pharmaceutical, Inc. 2022 Q4 - Results - Earnings Call Presentation

Collegium Pharmaceutical, Inc. (COLL) Q4 2022 Earnings Conference Call February 23, 2023, 04:30 PM ET Company Participants Christopher James - Vice President of Investor Relations at Collegium Pharmaceuticals Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chie...